Filament Health Corp
Filament Health Corp. operates as a clinical-stage natural psychedelic drug development company in Canada. The company's leading drug candidates comprises PEX010 oral psilocybin, PEX020 oral psilocin, and PEX030 sublingual psilocin. It also develops AEX010 ayahuasca, which is in preclinical stage; and AEX020 monoamine oxidase inhibitor and is in preclinical stage. In addition, the company provide… Read more
Filament Health Corp (FLHLF) - Net Assets
Latest net assets as of December 2024: $1.75 Million USD
Based on the latest financial reports, Filament Health Corp (FLHLF) has net assets worth $1.75 Million USD as of December 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.41 Million) and total liabilities ($1.66 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.75 Million |
| % of Total Assets | 51.21% |
| Annual Growth Rate | 21.05% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 857.04 |
Filament Health Corp - Net Assets Trend (2020–2024)
This chart illustrates how Filament Health Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Filament Health Corp (2020–2024)
The table below shows the annual net assets of Filament Health Corp from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $1.75 Million | -29.87% |
| 2023-12-31 | $2.49 Million | -21.98% |
| 2022-12-31 | $3.19 Million | -80.71% |
| 2021-12-31 | $16.55 Million | +1934.37% |
| 2020-12-31 | $813.64K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Filament Health Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3600927700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $37.87 Million | 2167.29% |
| Total Equity | $1.75 Million | 100.00% |
Filament Health Corp Competitors by Market Cap
The table below lists competitors of Filament Health Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Adial Pharmaceuticals Inc
NASDAQ:ADIL
|
$1.80 Million |
|
Observe Medical Asa
OL:OBSRV
|
$1.80 Million |
|
Kia Lim Bhd
KLSE:6211
|
$1.81 Million |
|
Wi2Wi Corporation
V:YTY
|
$1.81 Million |
|
TAKE-TWO INTERACT (TKE.SG)
STU:TKE
|
$1.80 Million |
|
Fund.com Inc
PINK:FNDM
|
$1.80 Million |
|
Gema Grahasarana Tbk
JK:GEMA
|
$1.80 Million |
|
Chewathai Public Company Limited
BK:CHEWA
|
$1.80 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Filament Health Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,491,569 to 1,747,248, a change of -744,321 (-29.9%).
- Net loss of 4,970,272 reduced equity.
- New share issuances of 135,000 increased equity.
- Other factors increased equity by 4,090,951.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-4.97 Million | -284.46% |
| Share Issuances | $135.00K | +7.73% |
| Other Changes | $4.09 Million | +234.14% |
| Total Change | $- | -29.87% |
Book Value vs Market Value Analysis
This analysis compares Filament Health Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.92x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.95x to 2.92x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $0.00 | $0.02 | x |
| 2021-12-31 | $0.10 | $0.02 | x |
| 2022-12-31 | $0.02 | $0.02 | x |
| 2023-12-31 | $0.01 | $0.02 | x |
| 2024-12-31 | $0.01 | $0.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Filament Health Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -284.46%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -805.98%
- • Asset Turnover: 0.18x
- • Equity Multiplier: 1.95x
- Recent ROE (-284.46%) is below the historical average (-267.41%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -55.90% | -5694.53% | 0.01x | 1.08x | $-10.91 Million |
| 2022 | -515.65% | -4517.55% | 0.08x | 1.48x | $-16.79 Million |
| 2023 | -213.60% | -249.75% | 0.38x | 2.24x | $-5.57 Million |
| 2024 | -284.46% | -805.98% | 0.18x | 1.95x | $-5.14 Million |
Industry Comparison
This section compares Filament Health Corp's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Filament Health Corp (FLHLF) | $1.75 Million | -55.90% | 0.95x | $1.80 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |